Gerresheimer: A Rally in the Shadow of an Unfinished Balance Sheet

Gerresheimer shares rebound over 60%, but a wide analyst price gap (€12.90–€46) and missing audited 2025 accounts keep fundamental uncertainty high.

Gerresheimer’s stock has staged a breathtaking recovery from its February trough, surging more than 60% – yet the euphoria is tempered by a yawning gap in analyst opinion and a still-unpublished audited financial statement. The packaging and drug-delivery specialist finds itself caught between a technical rebound and fundamental uncertainty.

The shares bottomed at 14.90 euros in February, according to one data set, and later appeared to touch a fresh low of 15.57 euros. From that depressed base, the stock has climbed sharply, closing at 26.08 euros in the most recent session. That puts the equity roughly 10% above its 50-day moving average of 23.22 euros, but still nearly 48% below its 52-week high of 50.25 euros. The run-up has come at a cost: the relative strength index hit 82.3, flashing overbought signals after such a steep ascent. On a 12-month view, the shares remain down more than 45%.

The analyst community is deeply fractured. At one extreme, JPMorgan slaps an “Overweight” rating and a 46-euro target, implying a near-double. At the opposite end, UBS has “Sell” and 12.90 euros – a 50% haircut. Jefferies sits near the middle with a “Hold” and 26.80 euros, while Barclays and Bernstein Research see the stock at 19 euros and 18.90 euros respectively, both “Underweight” or “Underperform”. That spread – from 12.90 to 46 euros – is far wider than normal, reflecting a market that cannot agree on Gerresheimer’s earnings power until the numbers are on the table.

That accounting black hole is the crux. Gerresheimer has yet to file its audited annual and consolidated accounts for 2025, citing ongoing investigations into business transactions from 2024 and 2025. In April, 96% of holders of its 870-million-euro Schuldschein loan agreed to extend the deadline until the end of September 2026 – the company itself had set a softer target of June 2026, with a Q1 2026 quarterly report expected soon after. Until the certified accounts appear, any valuation remains provisional.

Operational headwinds are piling up in the meantime. Margin pressure persists, and the integration of Bormioli has thrown up difficulties. The wider sector tells the story: online pharmacies such as Redcare and DocMorris surged 9.2% and 7.7% on a regulatory tweak to pharmacy fixed fees, while traditional medtech names continue to suffer cost squeezes. Gerresheimer’s annualised 30-day volatility runs at nearly 48% – a number that neatly captures the unresolved questions around margins and growth.

On the positive side, the company has not been idle. In late May it announced a collaboration with Newel Health to combine its drug-delivery and digital-health expertise with Newel’s AI-powered H-Core platform for integrated digital therapies. The move is strategic, but in the short term the market is focused on the balance sheet, not the product pipeline.

The next catalyst is clear: if Gerresheimer delivers the audited 2025 accounts in June as previously indicated, the re-rating argument could gain tangible support. If that deadline slips, attention will shift to the September 2026 creditor extension, and renewed selling pressure. For now, the stock hovers just below its 200-day moving average of 26.31 euros – a level that will test whether this rally has legs or is merely a bear-market bounce.